Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.
about
Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategiesA highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS modelRetroviral DNA IntegrationControl of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus.Nonhuman primate models for HIV cure research.Chronic binge alcohol consumption does not diminish effectiveness of continuous antiretroviral suppression of viral load in simian immunodeficiency virus-infected macaques.IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques.Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaquesDetection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral TherapyCharacterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.Plasmodium inui infection reduces the efficacy of a simian immunodeficiency virus DNA vaccine in a rhesus macaque model through alteration of the vaccine-induced immune response.Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agentsInvestigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS.The role of cytokines in the establishment, persistence and eradication of the HIV reservoirRobust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infectionEffect of combination antiretroviral therapy on Chinese rhesus macaques of simian immunodeficiency virus infectionTherapeutic imprinting of the immune system: towards a remission of AIDS in primates?Antiviral Activity of Bictegravir and Cabotegravir Against Integrase Inhibitor Resistant SIVmac239 and HIV-1.Differential sensitivities of retroviruses to integrase strand transfer inhibitorsNonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy.Correlates of Protection Against SIVmac251 Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors.
P2860
Q26825814-0B96450D-EFBC-42C0-835E-F77A26B1DC02Q27344720-4ECD5A6B-0EF5-4E40-A056-F4546E574CE2Q28596842-D2F57E6E-0681-41E5-9094-6F6E8B97AAF3Q30422006-14C91C02-D60B-410B-909A-2B97927CC4C6Q34059575-63352A3B-9A09-4AA6-A755-F5FEACB64166Q34198191-278EDF1A-F14A-4543-89D5-648BAB52A7A8Q34407781-7D6F570B-BDF0-42A0-842E-D393BBC26351Q35022815-A263C9A5-FAF5-4262-8828-CB251649A0FFQ35197395-4EB929FE-1D2E-4939-A954-E4642487F770Q35432739-1D67831B-9D8B-467A-87B8-717C1A743A99Q35641179-FA3D9127-6DAE-4170-935B-0F7971B61214Q36281109-A74EE4A4-7EAB-4A73-B2FB-F1BDBB5FE958Q36379235-21CBE271-76EC-4505-A2B9-654392AF7C0FQ36389032-200C3D8B-0147-4F06-9FF6-420F65AA1B6FQ36601857-88C37C95-B2B0-4591-9F98-47352B3295C0Q36760224-4258EDDC-7D33-4E90-A0D7-0143628B23FBQ37109010-75B7E985-9469-437B-BDF8-68288EA93511Q37157209-64F9543B-811A-42D4-874F-50CB26926CFFQ37169285-D354ADF2-D1C4-452D-9511-7DDC4DEBDDA2Q37258308-2287305C-0ADB-42E0-9796-D9B23BD63299Q41814233-1095928F-330F-4432-B65E-0EB44B56A03AQ41935102-2988312A-1FC7-4134-9E57-4E240B2055F7Q42017701-F8C3ED9E-2BE3-4021-B7BB-1037BA45FBB8Q45326424-9AA81669-4AB7-4330-8315-EE24C489BC7CQ53692345-ED118925-8D0D-4307-B461-D96F55D229A8
P2860
Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Response of a simian immunodef ...... during antiretroviral therapy.
@ast
Response of a simian immunodef ...... during antiretroviral therapy.
@en
type
label
Response of a simian immunodef ...... during antiretroviral therapy.
@ast
Response of a simian immunodef ...... during antiretroviral therapy.
@en
prefLabel
Response of a simian immunodef ...... during antiretroviral therapy.
@ast
Response of a simian immunodef ...... during antiretroviral therapy.
@en
P2093
P2860
P50
P921
P356
P1433
P1476
Response of a simian immunodef ...... during antiretroviral therapy.
@en
P2093
Andrea Savarino
Enrico Garaci
Fausto Titti
Jack Greenhouse
Jake Yalley-Ogunro
Matt Collins
Nunzio Iraci
Sandro Norelli
P2860
P2888
P356
10.1186/1742-4690-7-21
P577
2010-03-16T00:00:00Z
P5875
P6179
1001115105